专利检索 ap:("Patrick L. Iversen" OR "John E. Mata" OR "Vincent H. Gattone, II") AND inv:"Vincent H. Gattone, II" 第 1 页

1.

发明授权
Antisense to c-myc for treatment of polycystic kidney disease 有权
标题翻译：用于治疗多囊肾病的c-myc反义词

公开(公告)号：US06875747B1

公开(公告)日：2005-04-05

申请号：US09577250

申请日：2000-05-24

申请人： Patrick L. Iversen , John E. Mata , Vincent H. Gattone, II

发明人： Patrick L. Iversen , John E. Mata , Vincent H. Gattone, II

IPC分类号： A61K38/00 , C12N15/113 , C07H21/04 , A61K48/00 , C12N15/00

CPC分类号： C12N15/1135 , A61K38/00 , C12N2310/314 , C12N2310/3233

摘要： A method of treating polycystic kidney disease by administering an oligonucleotide antisense to c-myc is described. The antisense oligonucleotide is preferably a morpholino oligonucleotide.

摘要翻译： 描述了通过施用对c-myc反义的寡核苷酸治疗多囊肾病的方法。反义寡核苷酸优选为吗啉代寡核苷酸。

2.

发明授权
Treatment of polycystic kidney disease using vasopressin V.sub.2 receptor antagonists 有权
标题翻译：使用加压素V2受体拮抗剂治疗多囊肾病

公开(公告)号：US5972882A

公开(公告)日：1999-10-26

申请号：US211396

申请日：1998-12-14

申请人： Vincent H. Gattone, II

发明人： Vincent H. Gattone, II

IPC分类号： A61K38/11 , A61K38/12 , A61K38/00

CPC分类号： A61K38/11 , A61K38/12

摘要： The present invention is directed to the novel treatment of ARPKD and ADPKD by administering a pharmacologically effective amount of a V.sub.2 receptor antagonist. Orally active V.sub.2 receptor antagonists such as OPC-31260, OPC-41061, SR121463A and VPA-985 are administered alone, or in combination to mammalian PKD subjects to reduce the cAMP generated by the increased expression of AVP-V.sub.2 receptor, AQP2 and AQP3, thereby reducing and/or preventing cyst enlargement.

摘要翻译： 本发明涉及通过施用药理学有效量的V2受体拮抗剂来治疗ARPKD和ADPKD。口服活性的V2受体拮抗剂例如OPC-31260，OPC-41061，SR121463A和VPA-985单独施用或组合施用于哺乳动物PKD受试者以减少由AVP-V2受体，AQP2和AQP3的表达增加产生的cAMP，从而减少和/或预防囊肿扩大。